07. Recombinant Zoster Vaccine (RZV) Second-Dose Completion in Adults Age 50‒64 Years in the United States

BACKGROUND: In 2018, CDC recommended a highly efficacious adjuvanted recombinant zoster vaccine (RZV, Shingrix) as a 2-dose series for prevention of herpes zoster (HZ) for immunocompetent persons age ≥50 years, with the 2(nd) dose recommended 2–6 months after the 1(st) dose. Among Medicare beneficia...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Jessica, Gray, Elizabeth B, Anderson, Tara, Sharkey, Sarah M, Dooling, Kathleen L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644796/
http://dx.doi.org/10.1093/ofid/ofab466.210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644796/
http://dx.doi.org/10.1093/ofid/ofab466.210

Ejemplares similares